Advances in pharmacotherapy for hypertension and its comorbidities
高血压及其合并症的药物治疗进展

摘要

高血压是指当血液在血管内流动时，会使血管壁上的压力值持续高于正常水平的现象，其发病原因复杂多样，包括遗传因素、环境因素等，高血压的发病率、致残率和病死率都相当高。随着社会老龄化进程加快以及人们生活节奏日益紧张，高血压病已成为威胁人类健康最常见的疾病之一，且有逐年上升趋势，严重影响人民群众身体健康及生活质量。为了确保大众的身体和心理健康，以及提升他们的生活品质，积极的降血压治疗显得尤为关键。患有高血压合并症的病人在接受降压治疗时，与没有合并症的病人有所不同，在进行降压治疗的过程中不仅需要关注高血压的基本情况，还需要考虑合并症的独特性质。

Abstract

Essential hypertension is often referred to as hypertension, the main clinical symptom is the rise of systemic arterial pressure, the causes of which are complex and diverse, including genetic factors, environmental factors, etc., and the incidence, disability and mortality rates of hypertension are quite high. With the acceleration of the aging process of society and the increasingly tense pace of people's lives, hypertension has become one of the most common diseases threatening human health, and it is increasing year by year, seriously affecting the health and quality of life of the people. In order to ensure the physical and mental health of the general public, as well as to improve their quality of life, aggressive blood pressure lowering treatment is crucial. Patients with hypertensive comorbidities are treated differently from patients without comorbidities when receiving antihypertensive therapy, and it is necessary to pay attention not only to the basic condition of hypertension but also to the unique nature of comorbidities.